Drug Trial Radar · NCT02369081
Optimum Treatment for Drug-Resistant Hypertension
Last checked: Nov 19, 2026Latest source record: Jul 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
348
Actual
Start
May 2009
Primary completion
Jul 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- University of CambridgeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- British Heart Foundation
- First posted
- Feb 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was recommended by NICE, as part of its 2006 guidance for the treatment of hypertension, and is urgently required to provide evidence for the treatment recommendations in patients with resistant hypertension. The study will be a randomised placebo-controlled double-blind crossover comparison of an α-blocker (α), β-blocker (β), and K+-sparing diuretic (∆). Patients will have a BP at entry above target on ABPM or home monitoring despite supervised administration of maximum tolerated doses of A+C+D. Over 48 weeks they will then receive, in random order either placebo or two doses each of doxazosin (α), bisoprolol (β) or spironolactone (∆). Each treatment cycle will last 12 weeks, with a forced dose-doubling at 6 weeks. The time course for the study will be similar to study one. 340 patients will provide 90% power, at α=0.01 to detect a 3 mmHg overall difference in home sBP between any one drug and placebo, with spironolactone hypothesized to be best overall. The study will be able to detect a 6 mmHg difference in sBP between each subject's best and second-best drug predicted by tertile of plasma renin, justifying routine use of the measurement in patients with resistant hypertension.
Conditions
- Hypertension, Resistant to Conventional Therapy
Interventions
SpironolactoneDrug
Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
BisoprololDrug
Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
DoxazosinDrug
Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
PlaceboDrug
Placebo treatment for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment arm comparison according to home blood pressure measurementTime frame: 48 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
NHS Ayrshire
Ayrshire, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
University of Birmingham
Birmingham, United Kingdom
University of Cambridge - Addenbrookes Hospital
Cambridge, United Kingdom
NHS Tayside/University of Dundee
Dundee, United Kingdom
NHS Lothian/University of Edinburgh
Edinburgh, United Kingdom
Royal Devon & Exeter NHS Foundation Trust
Exeter, United Kingdom
NHS Greater Glasgow and Clyde/University of Glasgow
Glasgow, United Kingdom
Ixworth GP Practice
Ixworth, United Kingdom
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Barts and the London School of Medicine and Dentistry
London, United Kingdom
Guys and St Thomas' NHS Foundation Trust
London, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
Central Manchester University Hospitals NHS Foundation Trust
Manchester, United Kingdom
Norfolk and Norwich University Hospital NHS Trust
Norwich, United Kingdom
West Hertfordshire Hospitals NHS Trust
Watford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.